Soumya Palliyil
As CEO and co-founder, Dr Soumya Palliyil is currently leading the creation of Brigid Biologics, a novel antifungal therapeutics spinout company from the University of Aberdeen supported by the Scottish Enterprise -High Growth Spinout Programme. Soumya Palliyil is also the head of Scottish Biologics Facility with 15+ years of experience in antibody engineering and in charge of several antibody discovery and development projects with academic and commercial partners. Soumya was the recipient of the prestigious British Council/Commonwealth Scholarship for her MRes at the University of Aberdeen. Her PhD in Medical Biotechnology was funded through the Knowledge Transfer Partnership (KTP) between the University of Aberdeen and Pfizer Inc and she was the award-winning associate for the best KTP in Scotland (2011). She received the Royal Society of Edinburgh Commercialisation Fellowship and is a member of the Royal Society of Biology. Recently she led Brigid Biologics at the Converge Challenge 2023 competition for Scottish University spinouts and startups and came runner-up in the main prize category for high growth businesses.